中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
11期
1962-1963
,共2页
肿瘤标志物%乳腺肿瘤%诊断
腫瘤標誌物%乳腺腫瘤%診斷
종류표지물%유선종류%진단
Tumor markers%Breast Neoplasms%Diagnosis
目的 探讨肿瘤标志物CA153、CA125、CEA和SF联合检测在乳腺癌中的临床应用价值.方法 利用化学发光免疫方法检测60例乳腺良性疾病(乳腺良性疾病组)和40例健康体检者(对照组)以及60例乳腺癌患(乳腺癌组)治疗前后血清CA15-3、CA125、CEA和SF的水平,并进行分析.结果 乳腺癌组治疗前CA153、CA125、CEA、SF水平[(52.8±21.3)u/ml、(44.2±20.1)ng/ml、(8.9±5.2)ng/ml、(350.5±113.8)ng/ml]均显著高于乳腺良性疾病组[(17.3±8.8)u/ml、(15.6±8.5)u/ml、(2.0±0.8)u/ml、(1220.7±46.91)ng/ml](t=2.671,t=2.684,t=2.898,t=2.844,P均＜0.01);乳腺癌组患者血清CA15-3、CA125、CEA和SF治疗前的水平(同上)明显高于治疗后[(25.5±3.7)u/ml、(15.0±8.4)u/ml、(4.6±3.3)ng/ml、(98.5±58.6)ng/ml](t=2.210,t=2.165,t=2.224,t=2.234,P均＜0.05);乳腺良性疾病组与正常对照组差异无统计学意义(t=1.644,t=1.757,t=1.67,t=1.741,P均＞0.05);乳腺癌组CA153+CA125+CEA+SF四项联检阳性率53.3%低于CA153(56.7%)、CA125(58.3%)、CEA(63.3%)、SF(68.3%)(χ~2=2.52,χ~2=2.652,P＞0.05;χ~2=3.85,χ~2=3.90,χ~2=3.98,P＜0.05).结论 血清CA15-3、CA125、CEA、SF联合检测可提高乳腺癌的阳性检出率,对乳腺癌的早期诊断、疗效监测以及预后判断均有重要意义.
目的 探討腫瘤標誌物CA153、CA125、CEA和SF聯閤檢測在乳腺癌中的臨床應用價值.方法 利用化學髮光免疫方法檢測60例乳腺良性疾病(乳腺良性疾病組)和40例健康體檢者(對照組)以及60例乳腺癌患(乳腺癌組)治療前後血清CA15-3、CA125、CEA和SF的水平,併進行分析.結果 乳腺癌組治療前CA153、CA125、CEA、SF水平[(52.8±21.3)u/ml、(44.2±20.1)ng/ml、(8.9±5.2)ng/ml、(350.5±113.8)ng/ml]均顯著高于乳腺良性疾病組[(17.3±8.8)u/ml、(15.6±8.5)u/ml、(2.0±0.8)u/ml、(1220.7±46.91)ng/ml](t=2.671,t=2.684,t=2.898,t=2.844,P均＜0.01);乳腺癌組患者血清CA15-3、CA125、CEA和SF治療前的水平(同上)明顯高于治療後[(25.5±3.7)u/ml、(15.0±8.4)u/ml、(4.6±3.3)ng/ml、(98.5±58.6)ng/ml](t=2.210,t=2.165,t=2.224,t=2.234,P均＜0.05);乳腺良性疾病組與正常對照組差異無統計學意義(t=1.644,t=1.757,t=1.67,t=1.741,P均＞0.05);乳腺癌組CA153+CA125+CEA+SF四項聯檢暘性率53.3%低于CA153(56.7%)、CA125(58.3%)、CEA(63.3%)、SF(68.3%)(χ~2=2.52,χ~2=2.652,P＞0.05;χ~2=3.85,χ~2=3.90,χ~2=3.98,P＜0.05).結論 血清CA15-3、CA125、CEA、SF聯閤檢測可提高乳腺癌的暘性檢齣率,對乳腺癌的早期診斷、療效鑑測以及預後判斷均有重要意義.
목적 탐토종류표지물CA153、CA125、CEA화SF연합검측재유선암중적림상응용개치.방법 이용화학발광면역방법검측60례유선량성질병(유선량성질병조)화40례건강체검자(대조조)이급60례유선암환(유선암조)치료전후혈청CA15-3、CA125、CEA화SF적수평,병진행분석.결과 유선암조치료전CA153、CA125、CEA、SF수평[(52.8±21.3)u/ml、(44.2±20.1)ng/ml、(8.9±5.2)ng/ml、(350.5±113.8)ng/ml]균현저고우유선량성질병조[(17.3±8.8)u/ml、(15.6±8.5)u/ml、(2.0±0.8)u/ml、(1220.7±46.91)ng/ml](t=2.671,t=2.684,t=2.898,t=2.844,P균＜0.01);유선암조환자혈청CA15-3、CA125、CEA화SF치료전적수평(동상)명현고우치료후[(25.5±3.7)u/ml、(15.0±8.4)u/ml、(4.6±3.3)ng/ml、(98.5±58.6)ng/ml](t=2.210,t=2.165,t=2.224,t=2.234,P균＜0.05);유선량성질병조여정상대조조차이무통계학의의(t=1.644,t=1.757,t=1.67,t=1.741,P균＞0.05);유선암조CA153+CA125+CEA+SF사항련검양성솔53.3%저우CA153(56.7%)、CA125(58.3%)、CEA(63.3%)、SF(68.3%)(χ~2=2.52,χ~2=2.652,P＞0.05;χ~2=3.85,χ~2=3.90,χ~2=3.98,P＜0.05).결론 혈청CA15-3、CA125、CEA、SF연합검측가제고유선암적양성검출솔,대유선암적조기진단、료효감측이급예후판단균유중요의의.
Objective To study the clinical significance of sernm CA153,CA125 and CEA test in breast cancer.Methods The levels of CA153,CA125,carcinoembryonic antigen(CEA)and ferritin were measured in 60 patients with breast cancer(breast cancer group),36 patients with benign breast diseases(benign breast diseases group)and 40 healthy people(control group)by chemiluminometry.The four indices were compared and analyzed for their complementary diagnostic value to breast cancer.Results The levels of CA153,CA125,CEA,SF[(52.8±21.3)u/ml,(44.2±20.1)ng/ml,(8.9±5.2)ng/ml,(350.5±113.8)ng/ml]in breast cancer group were significantly higher than that of benign breast disease group[(17.3±8.8)u/ml,(15.6±8.5)u/ml,(2.0±0.8)u/ml,(1220.7±46.91)ng/ml](t=2.671,t=2.684,t=2.898,t=2.844,P＜0.01);The levels of CA153,CA125,CEA and SF pretreatment in breast cancer group were significantly higher than that after treatment[(25.5±3.7)u/ml,(15.0±8.4)u/ml,(4.6±3.3)ng/ml,(98.5±58.6)ng/ml](t=2.210,t=2.165,t=2.224,t=2.234,P＜0.05);The positive rate of 53.3%in breast cancer group for CA153+CA125+CEA+SF were lower than that CA153(56.7%),CA125(58.3%),CEA(63.3%),SF(68.3%)(χ~2=2.52,χ~2=2.652,P＞0.05;χ~2=3.85,χ~2=3.90,χ~2=3.98,P＜0.05);joint determination of CA153+CEA+SF experimental efficient 89.0%higher than the other four groups of the joint determination,but had no signiflcanle(χ~2=2.78,χ~2=3.10,χ~2=2.99,χ~2=3.01,P＞0.05).Conclusion The positive rate may be increased by combining test of serum CA153,CA125,CEA and ferritin in breast cancer.Thus the combined test might be of high value for the early diagnosis,improving the therapeutic effect and prognosis of breast cancer.
